Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. [electronic resource]
Producer: 20160418Description: 3858-65 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- classification
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Ataxia Telangiectasia Mutated Proteins -- blood
- Biomarkers, Tumor -- blood
- Biopsy, Needle
- Disease-Free Survival
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- classification
- Paclitaxel -- administration & dosage
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Proportional Hazards Models
- Prospective Studies
- Stomach Neoplasms -- classification
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.